EC
PTCT icon

Elequin Capital’s PTC Therapeutics PTCT Stock Holding History

Elequin Capital’s Portfolio PTCT Stock Details PTCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-46
Closed -$3.49K – 708
2025
Q4 		$3.49K Buy
+46
New +$3.34K ﹤0.01% 331
2025
Q1 		– Sell
-2
Closed -$90 – 578
2024
Q4 		$90 Sell
2
-163
-99% -$6.98K ﹤0.01% 487
2024
Q3 		$6.12K Buy
+165
New +$5.52K ﹤0.01% 282
2024
Q2 		– Sell
-142
Closed -$4.13K – 322
2024
Q1 		$4.13K Buy
142
+135
+1,929% +$3.78K ﹤0.01% 162
2023
Q4 		$193 Sell
7
-3
-30% -$69 ﹤0.01% 336
2023
Q3 		$224 Sell
10
-314
-97% -$11.7K ﹤0.01% 363
2023
Q2 		$13.2K Buy
+324
New +$15.9K 0.01% 272
2023
Q1 		– Sell
-16
Closed -$611 – 492
2022
Q4 		$611 Buy
+16
New +$665 ﹤0.01% 613
2022
Q3 		– Sell
-27
Closed -$1K – 653
2022
Q2 		$1K Buy
27
+6
+29% +$210 ﹤0.01% 365
2022
Q1 		$1K Buy
+21
New +$809 ﹤0.01% 300

Other funds holding PTCT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $86.4B AUM 59.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return

Elequin Capital's PTCT Position: Q1 2026 in Review

Elequin Capital sold out of PTC Therapeutics (PTCT) in Q1 2026, closing a stake of 46 shares — an estimated $3.49K sold.

Elequin Capital first reported a position in PTCT in Q1 2022 and held it in 10 quarters. The position peaked at $13.2K in Q2 2023. 352 funds tracked by Wall St. Rank hold PTCT as of Q1 2026.

  • Elequin Capital reported no remaining PTC Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Elequin Capital sold 46 PTC Therapeutics shares in Q1 2026, an estimated $3.49K.
  • Elequin Capital first reported a position in PTC Therapeutics in Q1 2022 and held it in 10 quarters.
  • Elequin Capital's PTC Therapeutics position peaked at $13.2K in Q2 2023.
  • 352 funds tracked by Wall St. Rank held PTC Therapeutics as of Q1 2026.

Based on Elequin Capital's 13F filing for Q1 2026, filed 11 May 2026.